×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Making Better Go/No-Go Decisions: Improving Success Rates and Reducing Costs
Session Chair(s)
Joseph A DiMasi, PhD
Director of Economic Analysis and Research Associate Professor
Tufts Center for the Study of Drug Development, United States
This session will examine trends in success rates and recently developed methods which establish a set of factors that can be scored and combined to improve the predictability of approval for compounds that have undergone mid-stage clinical testing.
Learning Objective : Analyze the historical record concerning technical risks in clinical development of new drugs and biologics; Assess how clinical, compound, operational, and economic characteristics can be used to make better go/no-go development decisions.
Speaker(s)
APGAR Begets ANDI: What Drug Developers Can Learn from Orchestra Auditions and Crying Newborns
Wayne Rackoff, MD, MA
Janssen Research & Development, LLC, United States
Vice President, Clinical Oncology
Improving Phase 2 Go/No-Go Decision-Making with a Simple Scoring Algorithm
Joseph A DiMasi, PhD
Tufts Center for the Study of Drug Development, United States
Director of Economic Analysis and Research Associate Professor
Looking at Cost/Time/Risk/Value Scenarios to Improve Clinical Program Decision-Making
Rick Sax, DrMed, FACP
Pharma Design Solutions, Ltd., United Kingdom
Managing Director
Have an account?